CPH’s subsidiary Hemp Industries receives approval to sell new range of hemp extract products in Czech Republic
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma (ASX:CPH) today announced its subsidiary Hemp Industries has received regulatory approval for the sale of its new range of hemp extract-based products called ‘diCBDium’ in the Czech Republic.
It’s a significant move which will pave the way for the company to begin selling the product range to 396 pharmacies in the country, offering the THC-free diCBDium in three different concentrations of CBD (the acronym for cannabidiol, the products’ key ingredient) at 3%, 5% and 10%.
Creso Pharma has established itself as a leader in cannabidiol innovation, and is developing cannabis and hemp derived therapeutic grade CBD nutraceuticals and medical cannabis products across both human and animal health sectors.
Today’s development is the first of what the company hopes will be a string of similar announcements over the next six months, as it advances negotiations with other potential distributors in Slovakia, Austria and Central Europe.
Yet, CPH does remain a speculative investment and professional financial advice should be sought for those considering this stock for their portfolio.
Hemp Industries is also expecting a third order of its Hemp Protein from one of Slovakia’s largest bakeries, Pekarne Liptovsky Hradok (PLH) with the order being used to produce several top-quality protein bar products. These bars are to be sold in leading grocery chains like Tesco and Kaufland.
Hemp Industries has previously supplied PLH with a 500kg shipment of hemp protein in August 2016 and a 700kg shipment in December 2016.
Hemp’s non-THC diCBDium product line is used for regulating health and disease, physiological functions, supporting the central and peripheral nervous systems and in peripheral organs.
“Hemp Industries continues to build its profile as the leading supplier in the region of hemp extract and hemp protein products and this new range provides another opportunity for the Company to grow its customer base and revenues,” said Creso Pharma Chairman and Co-Founder Boaz Wachtel.
“We anticipate strong demand for the new range both in our existing markets and we also hope to build additional demand through distribution relationships in new markets across Central Europe.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.